MedTrace Logo

Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies

NCT01594502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 139

Last updated 2020-10-12

No results posted yet for this study

Summary

The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.

Conditions

Interventions

DRUG

Dutasteride

0.5 mg daily

DRUG

Placebo

Placebo Comparator

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Peter H Gann, MD, ScD · University of Illinois at Chicago

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-11-30
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01594502 on ClinicalTrials.gov